New developments for treatment and prevention of bone metastases.
To provide a critical review of recent trials of bone resorption inhibitory drugs (bisphosphonates and denosumab) for the treatment and the prevention of bone metastases in solid tumors. The bisphosphonate zoledronic acid is now part of the standard treatment for metastatic bone disease. Comparative trials in this setting between zoledronic acid and denosumab have shown superior (in breast and in prostate cancer) or noninferior (in other solid tumors) skeletal-related event-prevention activity for denosumab. Osteonecrosis of the jaw is the most important side-effect of both compounds. Recent data also indicate the potential of zoledronic acid to reduce the recurrence rate in breast cancer. Much progress has been accomplished for the treatment of tumor bone disease with bone resorption inhibitory drugs. Advances are now awaited in the setting of prevention of bone metastases.